Pamoja Capital

Mindgram is a science-based platform and mobile application focused on promoting complete mental wellness. It aims to enhance productivity by addressing stress and burnout among employees. The platform provides daily personalized coaching, psychological support, and group workshops, which can be accessed through chat or video calls. By offering these services, Mindgram enables individuals to develop effective skills and manage workplace challenges more effectively.

The Nue Co. Ltd. is a London-based company that specializes in producing nutritional supplements made from organic ingredients. Established in 2016, The Nue Co. focuses on creating products such as vitamins, milk protein, plant protein, magnesium, prebiotics, and probiotics, with an emphasis on traceability and quality. The company's formulation approach is rooted in simplicity and creativity, utilizing powerful organic foods rich in specific nutrients rather than artificial additives. Their supplements are free from toxic preservatives, flavorings, and sweeteners, ensuring that every ingredient is responsibly sourced and clinically validated. Additionally, The Nue Co. operates an online subscription platform for product distribution, while prioritizing environmentally friendly practices by limiting plastic packaging and striving to reduce their carbon footprint. Their mission is to provide science-backed supplements that promote overall health and wellness.

Mindgram is a science-based platform and mobile application focused on promoting complete mental wellness. It aims to enhance productivity by addressing stress and burnout among employees. The platform provides daily personalized coaching, psychological support, and group workshops, which can be accessed through chat or video calls. By offering these services, Mindgram enables individuals to develop effective skills and manage workplace challenges more effectively.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, that specializes in the development of non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company focuses on creating products that utilize formulated volatile anesthetics, which differ from traditional unformulated volatile anesthetics currently used only for general anesthesia. Vapogenix's product line is designed to alleviate pain associated with venipuncture, venous cannulation, and minor dermatological procedures, as well as to manage pain related to wound care and localized inflammation. By improving the pain management experience for patients, particularly hospitalized children undergoing venous access procedures, Vapogenix aims to enhance the efficiency and effectiveness of healthcare providers in their practices.

Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, that specializes in the development of non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company focuses on creating products that utilize formulated volatile anesthetics, which differ from traditional unformulated volatile anesthetics currently used only for general anesthesia. Vapogenix's product line is designed to alleviate pain associated with venipuncture, venous cannulation, and minor dermatological procedures, as well as to manage pain related to wound care and localized inflammation. By improving the pain management experience for patients, particularly hospitalized children undergoing venous access procedures, Vapogenix aims to enhance the efficiency and effectiveness of healthcare providers in their practices.